Wednesday, March 25, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Analysis

Analyst Upgrade Fuels Bullish Outlook for Newmont Mining Shares

Robert Sasse by Robert Sasse
December 10, 2025
in Analysis, Commodities, Gold & Precious Metals
0
Newmont Mining Stock
0
SHARES
28
VIEWS
Share on FacebookShare on Twitter

Shares of Newmont Mining, the world’s largest gold producer, are attracting significant investor attention following a notable analyst upgrade. Market experts point to a combination of robust operational performance and this fresh vote of confidence as key drivers behind the stock’s recent momentum. Having already posted substantial gains since the start of the year, the equity is now viewed as having room for further appreciation.

Strong Quarterly Results Underpin Confidence

The current optimism is firmly grounded in the company’s latest fundamental performance. Newmont’s third-quarter financial report surpassed market expectations, providing a solid foundation for its valuation:

  • Earnings: The company reported earnings per share (EPS) of $1.71, significantly exceeding the consensus estimate of $1.27.
  • Revenue: Quarterly revenue climbed to $5.52 billion, representing a 20% increase compared to the same period last year.
  • Dividend: A dividend of $0.25 per share was declared, reinforcing the stock’s appeal to income-focused investors.

This operational strength is seen by many market participants as justifying the stock’s impressive year-to-date rally, which has delivered gains exceeding 116%.

Should investors sell immediately? Or is it worth buying Newmont Mining?

Key Rating Revision Provides Impetus

The immediate catalyst for increased buying interest was a revised assessment from National Bankshares. The firm’s analysts reaffirmed their “Outperform” rating on Newmont while explicitly raising their price target from $110.00 to $120.00. This move is interpreted by observers as a clear signal of confidence in the corporation’s future trajectory. The market reaction was swift, with elevated trading volumes pushing the share price markedly higher on Tuesday.

Operational Milestones Support Long-Term View

Beyond the financial metrics and analyst actions, strategic operational progress is also contributing to the positive assessment. The successful ramp-up to commercial production at the Ahafo North project in Ghana represents a critical milestone expected to bolster future output. Investors are now watching to see if the shares can sustain their positive momentum and challenge recent highs around the €84 level.

Ad

Newmont Mining Stock: Buy or Sell?! New Newmont Mining Analysis from March 25 delivers the answer:

The latest Newmont Mining figures speak for themselves: Urgent action needed for Newmont Mining investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from March 25.

Newmont Mining: Buy or sell? Read more here...

Tags: Newmont Mining
Robert Sasse

Robert Sasse

About Dr. Robert Sasse Accomplished economist, entrepreneur, and profound expert in financial markets. Dr. Robert Sasse holds a doctorate in economics and combines academic rigor with practical entrepreneurial experience. His deep expertise in economic relationships and unwavering conviction for a free-market liberal economic order drives his mission to provide investors with well-founded knowledge and guidance.
Areas of Expertise:
  • Economic Theory and Practice
  • Free-Market Economics
  • Entrepreneurship and Business Strategy
  • Investment Philosophy
Dr. Sasse's unique combination of academic knowledge and real-world business experience enables him to provide investors with comprehensive insights that bridge theory and practice.

Related Posts

BioNano Genomics Stock
Analysis

BioNano Genomics Stock: A Tale of Operational Gains and Revenue Headwinds

March 25, 2026
Humacyte Stock
Analysis

Humacyte Shares Hit Record Low Amid Capital Raise and Strategic Shifts

March 25, 2026
Evolent Health Stock
AI & Quantum Computing

Evolent Health Bets on AI Leadership Amid Share Price Decline

March 25, 2026
Next Post
Marvell Technology Stock

Marvell Technology Shares Slide Amid Analyst Concerns Over Key Contracts

Nvidia Stock

Nvidia Clears Major Hurdle in China with Conditional Export Approval

Tesla Stock

Tesla's Stock: A Battle of Visions Between AI Dreams and Auto Realities

Recommended

Alphabet Stock

Alphabet Shares Face Regulatory Headwinds Despite Autonomous Driving Breakthrough

4 months ago
Dish Network Stock

Institutional Investors Show Diverging Views on Dish Network’s Future

7 months ago
Finance_ Trading ratings today (2)

Lakeland Financial Exceeds Expectations with Fourth Quarter Earnings

2 years ago
DeFi Technologies Stock

DeFi Technologies: Navigating Expansion Amidst Legal Headwinds

3 months ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Bloom Energy Broadcom Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Oracle Palantir PayPal Plug Power QuantumScape Realty Income Robinhood Rocket Lab USA Salesforce Strategy Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

MongoDB Strengthens Leadership Amid AI-Driven Growth Phase

Talphera Shares Slide as Funding Concerns Overshadow Clinical Progress

Hain Celestial Sheds Snack Division in Strategic Overhaul

Technology Sector Faces Mounting Headwinds as AI Hype Meets Macroeconomic Reality

Lumen’s AI Infrastructure Push Gains Recognition Amid Strategic Overhaul

Microsoft’s AI Ambitions Strain Finances as Cash Reserves Shrink

Trending

BioNano Genomics Stock
Analysis

BioNano Genomics Stock: A Tale of Operational Gains and Revenue Headwinds

by Kennethcix
March 25, 2026
0

BioNano Genomics has wrapped up its fiscal year 2025, presenting a financial picture marked by significant operational...

Humacyte Stock

Humacyte Shares Hit Record Low Amid Capital Raise and Strategic Shifts

March 25, 2026
Evolent Health Stock

Evolent Health Bets on AI Leadership Amid Share Price Decline

March 25, 2026
MongoDB Stock

MongoDB Strengthens Leadership Amid AI-Driven Growth Phase

March 25, 2026
Talphera Stock

Talphera Shares Slide as Funding Concerns Overshadow Clinical Progress

March 25, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • BioNano Genomics Stock: A Tale of Operational Gains and Revenue Headwinds
  • Humacyte Shares Hit Record Low Amid Capital Raise and Strategic Shifts
  • Evolent Health Bets on AI Leadership Amid Share Price Decline

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com